• Dong-Zi Yang
  • Georg Griesinger
  • Wei Wang
  • Fei Gong
  • Xiaoyan Liang
  • Hanwang Zhang
  • Yingpu Sun
  • Elke Kahler
  • Claire Pexman-Fieth
  • Jan I. Olofsson
  • Herman Tournaye
  • Zi-Jiang Chen

Lotus II, a randomized, open-label, multicenter, international study compared the efficacy and safety of oral dydrogesterone versus micronized vaginal progesterone (MVP) gel for luteal support in IVF. A prespecified subgroup analysis was performed on 239 Chinese mainland subjects from the overall study population (n = 1034), who were randomized to oral dydrogesterone 30 mg or 8% MVP gel 90 mg daily from the day of oocyte retrieval until 12 weeks of gestation. The aim was to demonstrate non-inferiority of oral dydrogesterone to MVP gel, assessed by the presence of a fetal heartbeat at 12 weeks of gestation. In the Chinese mainland subpopulation, there was a numerical difference of 9.4% in favor of oral dydrogesterone, with ongoing pregnancy rates at 12 weeks of gestation of 61.4% and 51.9% in the oral dydrogesterone and MVP gel groups, respectively (adjusted difference, 9.4%; 95% CI: −3.4 to 22.1); in the overall population, these were 38.7% and 35%, respectively (adjusted difference, 3.7%; 95% CI: −2.3 to 9.7). In both the Chinese mainland subpopulation and the overall population, dydrogesterone had similar efficacy and safety to MVP gel. With convenient oral administration, dydrogesterone has potential to transform luteal support treatment.

Original languageEnglish
Pages (from-to)175-183
Number of pages9
JournalGynecological Endocrinology
Volume36
Issue number2
DOIs
Publication statusPublished - 1 Feb 2020

    Research areas

  • Chinese mainland, dydrogesterone, luteal phase support, micronized vaginal progesterone gel, IVF, randomized clinical trial

ID: 49994428